Objective. To unearth the clinical efficacy of tacrolimus ointment + 3 % boric acid lotion joint Chinese angelica decoction in chronic perianal eczema. Methods. Patients with chronic perianal eczema admitted to hospital from June 2018 and June 2019 were retrospectively analyzed. Patients in the control group ( n = 38 ) underwent basic therapy with tacrolimus ointment + 3 % boric acid lotion, whereas those in the observation group ( n = 38 ) were given oral Chinese angelica decoction on the basis of the above therapy. Patient’s baseline information before therapy and clinical symptoms after therapy were observed and compared, including pruritus ani score, anus drainage and damp score, skin lesion score, skin lesion area score, life quality index score, and IL-2, IL-4, and IgE levels in serum. Overall efficacy in the two groups was also evaluated. Results. No significant differences were found in the baseline information between the observation group and control group before therapy. After therapy, pruritus ani score ( P = 0.023 ), anus drainage and damp score ( P = 0.041 ), skin lesion score ( P = 0.025 ), and skin lesion area score ( P = 0.035 ) of patients in the observation group were remarkably lower than those in the control group. Significantly higher release levels of clinical symptoms of patients in the observation group were indicated. With respect to the control group, the life quality score ( P = 0.020 ) and IgE level in serum ( P = 0.003 ) of patients in the observation group were significantly lower, while IL-4 level in serum was significantly higher ( P = 0.129 ). The therapy in the observation group achieved better clinical efficacy. Overall efficacy in the observation group was markedly favorable with respect to the control group. Conclusion. With respect to tacrolimus ointment + 3 % boric acid lotion, patients with chronic perianal eczema displayed better clinical efficacy after jointly being treated by Chinese angelica decoction.

Background. Mounting evidence has shown that sirtuin 1 (SIRT1), a class III histone deacetylase, alleviated several types of neuropathic pain in the spinal cord and dorsal root ganglion and regulated some aberrant behaviors in the ventral tegmental area (VTA) and the nucleus accumbens (NAc). Methods. In this context, the effect of SIRT1 on neuropathic pain in the VTA-NAc pathway was investigated in the model of chronic constrictive injury (CCI). Results. SIRT1 was localized in the VTA neurons in naive mice. The expression of SIRT1 was decreased in the contralateral VTA of CCI mice. After microinjection of SRT1720 (an activator of SIRT1) in the contralateral VTA of CCI mice, the established thermal hyperalgesia was attenuated. However, it was further exacerbated by EX-527 (an inhibitor of SIRT1). The elevated level of acetyl-histone 3 was reduced by SRT1720 but further elevated by EX-527 in the contralateral VTA of CCI mice. The increased expression of Fos in both VTA and NAc was downregulated by SRT1720 but further upregulated by EX-527 in CCI mice. Conclusions. The discovery of the effect of SIRT1 on neuropathic pain in the VTA represents an important step forward in understanding the analgesic mechanisms of the VTA-NAc pathway.